Risk Factors and Peculiarities of Cerebral Vessels Alteration in Patients With Type 2 Diabetes in Association With Cerebrovascular Disease

Дубинина, Инесса Ивановна; Jadnov, V A; Yankina, S V; Solovieva, A V; Grishunina, E A

doi:10.17816/pavlovj20123104-109

Cited by 2 publications

(3 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Одним из значимых факторов риска развития ОНМК и его неблагоприятного исхода является сахарный диабет (СД) [1,7,8]. По данным исследований последних лет >10% больных СД 2 типа погибают в результате ОНМК [9], причем существенная часть этих пациентов умирает в острой стадии болезни.…”

Section: Introductionunclassified

“…По данным исследований последних лет >10% больных СД 2 типа погибают в результате ОНМК [9], причем существенная часть этих пациентов умирает в острой стадии болезни. У пациентов, страдающих СД, риск ССО чрезвычайно высок, и профилактика ССО также должна проводиться на постоянной основе [7][8].…”

Section: Introductionunclassified

“…Данные доказательной медицины свидетельствуют о том, что раннее начало комплекса мер по вторичной профилактике ССО у лиц, перенесших ОНМК, способно значительно снизить риск развития повторного МИ [4][5][6][7][8][9]. Учитывая высокую социальную значимость ОНМК, представляется важным изучить качество медикаментозного лечения в реальной амбулаторно-поликлинической практике пациентов, перенесших ОНМК, в зависимости от наличия и отсутствия СД.…”

Section: Introductionunclassified

See 2 more Smart Citations

Quality of medication therapy in patients after stroke depending on presence/absence of diabetes: data from the outpatient stage of REGION-M registry

Марцевич¹,

Толпыгина²,

Загребельный³

et al. 2021

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To assess the quality of medication treatment in the polyclinic within 2 years after discharge, depending on presence/absence of diarecommended for patients with stroke before its development and betes.Material and methods. The study included 684 patients assigned to the City Polyclinic № 64 (Moscow), discharged from F.I. Inozemtsev City Clinical Hospital (Moscow) for a period from January 1, 2012 to April 30, 2017 with a diagnosis of stroke/transient ischemic attack, of which 122 were diagnosed with diabetes.Results. Before stroke, therapy was recommended for 67,3% of patients with diabetes and 54,7% without diabetes (p<0,01): statins — 15,5 and 14,4%, antiplatelet agents — 32,7 and 25,5%, angiotensinconverting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) — 41,4 and 37,9%, beta-blockers (BBs) — 9,1% and 7,8%, respectively. For the first 6 months after stroke, the rate of statin therapy increased to 39,6 and 39,2%, antiplatelet drugs — to 62,6 and 51,9%, ACE inhibitors/ARBs — to 68,2 and 66%, BBs — to 51,6 and 37,2%, respectively. Then, after 6 months it decreased again to 28,8 and 27,1% for statins, to 30,7 and 35,2% for antiplatelet agents, to 43,3 and 42,6% for ACE inhibitors/ARBs and remained the same for BBs, respectively. There were no significant differences in the prevalence of prescribing most drugs to patients with and without diabetes, both before and after stroke, with the exception of hypoglycemic medications.Conclusion. The therapy of patients with previous stroke, both with and without diabetes, recommended in the polyclinic, is characterized by an insufficient prescription rate of main drug classes necessary for secondary cardiovascular prevention at all follow-up stages.

show abstract

Section: Introductionunclassified

See 1 more Smart Citation

Quality of medication therapy in patients after stroke depending on presence/absence of diabetes: data from the outpatient stage of REGION-M registry

Марцевич¹,

Толпыгина²,

Загребельный³

et al. 2021

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

Risk factors of death in diabetes mellitus

Asfandiyarova

2016

Klin. med.

View full text Add to dashboard Cite

Objective. To study risk factors of death in diabetes mellitus (DM). Materials and methods. This prospective cohort study included 337 patients with compromised carbohydrate metabolism (36 with impaired fasting glycemia or impaired glucose tolerance, 80 with type 1 diabetes, 194 with type 2 diabetes, 27 with diabetes due to chronic pancreatitis). Mean follow-up was 11.2±4.8 years (from 1 January 1995 through 31 December 2014). We investigated causes and risk factors of death in patients with impaired carbohydrate metabolism. Results. 115 patients died during the study period. The most common causes of death of patients with type 1 and 2 diabetes are cardiovascular diseases and cancer. Risk factors of death in type 1 DM include cardiovascular disease, diabetic nephropathy and retinopathy. Patients die at a younger age due to early onset of the disease. In type 2 diabetes risk factors of death are cardiovascular and oncologic diseases, nephropathy, the use of insulin. Patients die in elderly and senile age due to the late onset of diabetes. Gender differences in mortality associated with type 1 and 2 diabetes mellitus were not observed. Conclusion. Main causes of death in patients with type 1 and 2 DM are cardiovascular diseases and cancer. Risk factors of death include macro - and microvascular complications.

show abstract

Risk Factors and Peculiarities of Cerebral Vessels Alteration in Patients With Type 2 Diabetes in Association With Cerebrovascular Disease

Cited by 2 publications

References 2 publications

Quality of medication therapy in patients after stroke depending on presence/absence of diabetes: data from the outpatient stage of REGION-M registry

Quality of medication therapy in patients after stroke depending on presence/absence of diabetes: data from the outpatient stage of REGION-M registry

Risk factors of death in diabetes mellitus

Contact Info

Product

Resources

About